Cure My Disease

Don't miss your cure!

 Log in / Sign up

Weekly shot helps people with obesity and prediabetes shed pounds and fix blood sugar

NCT ID NCT05040971

Disease control Sponsor: Novo Nordisk A/S Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a weekly injection of semaglutide (2.4 mg) in 207 adults with obesity and prediabetes. Participants received either the drug or a placebo for 12 months, plus lifestyle advice. The goal was to see how much weight they lost and whether their blood sugar returned to normal. The study is complete, and results showed significant weight loss and improved blood sugar levels compared to placebo.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

207 people

The number who actually took part.

Started

Sep 2021

Finished

Jul 2023

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male or female aged greater than or equal to 18 years at the time of signing informed consent. * BMI greater than or equal to 30.0 kg/m\^2 * Prediabetes defined as at least one of the following: * HbA1c between 6.0 and 6.4 percent (42 and 47 mmol/mol) (both inclusive) as measured by central laboratory at screening. * FPG between 5.5 and 6.9 mmol/L (99 and 125 mg/dL) (both inclusive) as measured by central laboratory at screening. Exclusion Criteria: * History of type 1 or type 2 diabetes. * Treatment with glucose-lowering agent(s) within 90 days before screening. * HbA1c greater than or equal to 6.5 percent (greater than or equal to 48 mmol/mol) as measured by central laboratory at screening. * FPG greater than or equal to 7.0mmol/L (126 mg/dL) as measured by central laboratory at screening. A self-reported change in body weight greater than 5 kg (11 lbs) within 90 days before screening irrespective of medical records. * Treatment with any medication for the indication of obesity within the past 90 days before screening.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Obesity are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder prediabetes syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Obesity

Contacts and locations

Locations

  • Aarhus Universitetshospital Diabetes og Hormonsygdomme

    Aarhus N, 8200, Denmark

  • C-endo Diab Endo Clin Calgery

    Calgary, Alberta, T2V 4J2, Canada

  • CHU de Quebec-Universite Laval

    Québec, G1V 4G2, Canada

  • Centre Medical Acadie

    Montreal, Quebec, H4N 2W2, Canada

  • Centre de recherché du CHUS

    Sherbrooke, Quebec, J1H 5N4, Canada

  • Centricity Research LMC

    Toronto, Ontario, M4G 3E8, Canada

  • Claremont Medical Practice

    Exmouth, EX8 2JF, United Kingdom

  • Clifton Medical Centre

    Rotherham, South Yorkshire, S65 1DA, United Kingdom

  • Clinique Medicine Urbaine du Quartier Latin, Inc.

    Montreal, Quebec, QC H2L 4E9, Canada

  • Ctr de Med Metab de Lanaudiere

    Terrebonne, Quebec, J6X 4P7, Canada

  • Diabetes Heart Research Centre

    Toronto, Ontario, M6G 1M2, Canada

  • Dr Anil K Gupta Med Prof Corp

    Toronto, Ontario, M9V 4B4, Canada

  • G.A. Research Associates Ltd.

    Moncton, New Brunswick, E1G 1A7, Canada

  • GP Direct

    Harrow, HA2 0RQ, United Kingdom

  • Guys Hospital

    London, SE1 9RT, United Kingdom

  • Hospital Clinico San Carlos

    Madrid, 28040, Spain

  • Hospital Gregorio Marañón

    Madrid, 28009, Spain

  • Hospital Infanta Luisa

    Seville, 41010, Spain

  • Hvidovre Hospital Endokrinologisk forsknings afsnit 159

    Hvidovre, 2650, Denmark

  • Institut universitaire de cardiologie

    Québec, G1V 4G5, Canada

  • LMC Clin Res Inc. Calgary

    Calgary, Alberta, T2H 2G4, Canada

  • LMC Clin Res Inc. Thornhill

    Concord, Ontario, L4K 4M2, Canada

  • LMC Clin Rsrch Inc. (Montreal)

    Saint-Laurent, Quebec, H4T 1Z9, Canada

  • LMC ClinRsrh Inc.Brampton

    Brampton, Ontario, L6S 0C6, Canada

  • LMC Clinical Research Inc. Oakville

    Oakville, Ontario, L6M 1M1, Canada

  • LMC Diabetes & Endocrinology (Barrie)

    Barrie, Ontario, L4N 7L3, Canada

  • LMC Endo Ctr (Etobicoke) Ltd

    Etobicoke, Ontario, M9R 4E1, Canada

  • LMC Research Inc. Ottawa

    Nepean, Ontario, K2J 0V2, Canada

  • Manna Research Mirabel

    Mirabel, Quebec, J7J 2K8, Canada

  • Milestone Research

    London, Ontario, N5W 6A2, Canada

  • MyHealth - Strensall Health Care Centre

    Strensall, YO32 5UA, United Kingdom

  • Nova Scotia Hlth Halifax

    Halifax, Nova Scotia, B3H 2Y9, Canada

  • Obesity Research Unit

    Helsinki, 00014, Finland

  • Ocean West Research Clinic

    Surrey, British Columbia, V3Z 2N6, Canada

  • Premier Clinical Trial Research Network (PCTRN)

    Hamilton, Ontario, L8M 1K7, Canada

  • StudyCor

    Jyväskylä, 40620, Finland

  • The Health Centre

    Bradford-on-Avon, BA15 1DQ, United Kingdom

  • The Staploe Medical Centre

    Soham, CB7 5JD, United Kingdom

  • Toronto Sleep Institute/MedSleep

    Toronto, Ontario, M4P 1P2, Canada

  • University Hospital Coventry - WISDEM Centre

    Coventry, CV2 2DX, United Kingdom

  • University of Calgary

    Calgary, Alberta, T2T 5C7, Canada

  • Weight Wise Clinic

    Edmonton, Alberta, T6G 2R3, Canada

  • Wharton Med Clin Trials

    Hamilton, Ontario, L8L 5G8, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.